Development of 36 clones producing human monoclonal antibodies specific to cancer cells and their ability to inhibit cancer cell growth

Rieko Nakamura, Yoshiro Saikawa, Saiko Hosokawa, Kazumasa Fukuda, Koichiro Kumai, Tetsuro Kubota, Masaki Kitajima, Yuukou Kitagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The development of a specific antibody for cancer therapy could enable a potent strategy for overcoming cancer. As ideal immunotherapy, a human monoclonal antibody (HuMoAb) might have a useful antitumor effect without any lethal toxicities. Thirty-six unique clones producing HuMoAbs were successfully developed using tumor infiltrating lymphocytes collected from 28 patients with several malignant solid tumors. The 36 tumor-specific immunoglobins were found among 9,450 clones after 43 fusions by the conventional hybridoma method. Among these 36 HuMoAbs, 9 had a remarkable tumor-specific reaction and no reaction with normal tissues, as determined with quantum dots-streptavidin and a fluorescence microscope. The inhibition of cell proliferation by the HuMoAbs was evaluated with the MTT assay. Over 40% cell growth inhibition was confirmed with 4 of the 36 HuMoAbs. Two of the antibodies had highly-specific reactivity to carcinomatous lesions with strong growth inhibition and up to 94.3% inhibition of the control growth. In conclusion, 36 clones with HuMoAbs that have specific reactions with cancer cells were successfully established. These HuMoAbs might be utilized as either anticancer or drug delivery agents.

Original languageEnglish
Pages (from-to)1651-1657
Number of pages7
JournalAnticancer Research
Volume28
Issue number3 A
Publication statusPublished - 2008 May

Fingerprint

Clone Cells
Monoclonal Antibodies
Growth
Neoplasms
Tumor-Infiltrating Lymphocytes
Quantum Dots
Streptavidin
Antibodies
Hybridomas
Immunotherapy
Fluorescence
Cell Proliferation
Pharmaceutical Preparations

Keywords

  • Growth inhibition
  • Human monoclonal antibody
  • Hybridoma
  • Specificity to cancer cell

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Development of 36 clones producing human monoclonal antibodies specific to cancer cells and their ability to inhibit cancer cell growth. / Nakamura, Rieko; Saikawa, Yoshiro; Hosokawa, Saiko; Fukuda, Kazumasa; Kumai, Koichiro; Kubota, Tetsuro; Kitajima, Masaki; Kitagawa, Yuukou.

In: Anticancer Research, Vol. 28, No. 3 A, 05.2008, p. 1651-1657.

Research output: Contribution to journalArticle

Nakamura, Rieko ; Saikawa, Yoshiro ; Hosokawa, Saiko ; Fukuda, Kazumasa ; Kumai, Koichiro ; Kubota, Tetsuro ; Kitajima, Masaki ; Kitagawa, Yuukou. / Development of 36 clones producing human monoclonal antibodies specific to cancer cells and their ability to inhibit cancer cell growth. In: Anticancer Research. 2008 ; Vol. 28, No. 3 A. pp. 1651-1657.
@article{a2cec7bfc674469498b9040cdcaba5da,
title = "Development of 36 clones producing human monoclonal antibodies specific to cancer cells and their ability to inhibit cancer cell growth",
abstract = "The development of a specific antibody for cancer therapy could enable a potent strategy for overcoming cancer. As ideal immunotherapy, a human monoclonal antibody (HuMoAb) might have a useful antitumor effect without any lethal toxicities. Thirty-six unique clones producing HuMoAbs were successfully developed using tumor infiltrating lymphocytes collected from 28 patients with several malignant solid tumors. The 36 tumor-specific immunoglobins were found among 9,450 clones after 43 fusions by the conventional hybridoma method. Among these 36 HuMoAbs, 9 had a remarkable tumor-specific reaction and no reaction with normal tissues, as determined with quantum dots-streptavidin and a fluorescence microscope. The inhibition of cell proliferation by the HuMoAbs was evaluated with the MTT assay. Over 40{\%} cell growth inhibition was confirmed with 4 of the 36 HuMoAbs. Two of the antibodies had highly-specific reactivity to carcinomatous lesions with strong growth inhibition and up to 94.3{\%} inhibition of the control growth. In conclusion, 36 clones with HuMoAbs that have specific reactions with cancer cells were successfully established. These HuMoAbs might be utilized as either anticancer or drug delivery agents.",
keywords = "Growth inhibition, Human monoclonal antibody, Hybridoma, Specificity to cancer cell",
author = "Rieko Nakamura and Yoshiro Saikawa and Saiko Hosokawa and Kazumasa Fukuda and Koichiro Kumai and Tetsuro Kubota and Masaki Kitajima and Yuukou Kitagawa",
year = "2008",
month = "5",
language = "English",
volume = "28",
pages = "1651--1657",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - Development of 36 clones producing human monoclonal antibodies specific to cancer cells and their ability to inhibit cancer cell growth

AU - Nakamura, Rieko

AU - Saikawa, Yoshiro

AU - Hosokawa, Saiko

AU - Fukuda, Kazumasa

AU - Kumai, Koichiro

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

AU - Kitagawa, Yuukou

PY - 2008/5

Y1 - 2008/5

N2 - The development of a specific antibody for cancer therapy could enable a potent strategy for overcoming cancer. As ideal immunotherapy, a human monoclonal antibody (HuMoAb) might have a useful antitumor effect without any lethal toxicities. Thirty-six unique clones producing HuMoAbs were successfully developed using tumor infiltrating lymphocytes collected from 28 patients with several malignant solid tumors. The 36 tumor-specific immunoglobins were found among 9,450 clones after 43 fusions by the conventional hybridoma method. Among these 36 HuMoAbs, 9 had a remarkable tumor-specific reaction and no reaction with normal tissues, as determined with quantum dots-streptavidin and a fluorescence microscope. The inhibition of cell proliferation by the HuMoAbs was evaluated with the MTT assay. Over 40% cell growth inhibition was confirmed with 4 of the 36 HuMoAbs. Two of the antibodies had highly-specific reactivity to carcinomatous lesions with strong growth inhibition and up to 94.3% inhibition of the control growth. In conclusion, 36 clones with HuMoAbs that have specific reactions with cancer cells were successfully established. These HuMoAbs might be utilized as either anticancer or drug delivery agents.

AB - The development of a specific antibody for cancer therapy could enable a potent strategy for overcoming cancer. As ideal immunotherapy, a human monoclonal antibody (HuMoAb) might have a useful antitumor effect without any lethal toxicities. Thirty-six unique clones producing HuMoAbs were successfully developed using tumor infiltrating lymphocytes collected from 28 patients with several malignant solid tumors. The 36 tumor-specific immunoglobins were found among 9,450 clones after 43 fusions by the conventional hybridoma method. Among these 36 HuMoAbs, 9 had a remarkable tumor-specific reaction and no reaction with normal tissues, as determined with quantum dots-streptavidin and a fluorescence microscope. The inhibition of cell proliferation by the HuMoAbs was evaluated with the MTT assay. Over 40% cell growth inhibition was confirmed with 4 of the 36 HuMoAbs. Two of the antibodies had highly-specific reactivity to carcinomatous lesions with strong growth inhibition and up to 94.3% inhibition of the control growth. In conclusion, 36 clones with HuMoAbs that have specific reactions with cancer cells were successfully established. These HuMoAbs might be utilized as either anticancer or drug delivery agents.

KW - Growth inhibition

KW - Human monoclonal antibody

KW - Hybridoma

KW - Specificity to cancer cell

UR - http://www.scopus.com/inward/record.url?scp=45949088367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949088367&partnerID=8YFLogxK

M3 - Article

C2 - 18630522

AN - SCOPUS:45949088367

VL - 28

SP - 1651

EP - 1657

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -